Pfizer › Financials
Pfizer financials
PFETen years from Pfizer’s own SEC filings. Fiscal years end in December.
Income statement
| Dec 2016fiscal year | Dec 2017fiscal year | Dec 2018fiscal year | Dec 2019fiscal year | Dec 2020fiscal year | Dec 2021fiscal year | Dec 2022fiscal year | Dec 2023fiscal year | Dec 2024fiscal year | Dec 2025fiscal year | Last 12 monthsto Jun 2026 | Latest quarterJun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.82B | $52.55B | $40.83B | $40.91B | $41.65B | $73.64B | $91.79B | $50.91B | $63.63B | $62.58B | $63.70B | — |
| Net income | $7.21B | $21.31B | $11.15B | $16.03B | $9.16B | $21.98B | $31.37B | $2.12B | $8.03B | $7.77B | $4.33B | — |
| Earnings per share, diluted | $1.17 | $3.52 | $1.87 | $2.82 | $1.63 | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 | — | — |
Balance sheet
| Dec 2016fiscal year | Dec 2017fiscal year | Dec 2018fiscal year | Dec 2019fiscal year | Dec 2020fiscal year | Dec 2021fiscal year | Dec 2022fiscal year | Dec 2023fiscal year | Dec 2024fiscal year | Dec 2025fiscal year | Last 12 monthsto Jun 2026 | Latest quarterJun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.60B | $1.34B | $1.14B | $1.30B | $1.78B | $1.94B | $416.0M | $2.85B | $1.04B | $1.14B | — | $976.0M |
| Total assets | $171.62B | $171.80B | $159.42B | $167.49B | $154.23B | $181.48B | $197.21B | $226.50B | $213.40B | $208.16B | — | $201.13B |
| Debt | $31.40B | $37.08B | $37.69B | $37.42B | $4.00B | $37.83B | $35.44B | $63.79B | $61.15B | $64.64B | — | $63.10B |
| Total liabilities | $111.78B | $100.14B | $95.66B | $104.04B | $90.76B | $104.01B | $101.29B | $137.21B | $124.90B | $121.39B | — | $115.64B |
| Shareholders' equity | $59.54B | $71.31B | $63.41B | $63.14B | $63.24B | $77.20B | $95.66B | $89.01B | $88.20B | $86.48B | — | $85.19B |
Cash flow
| Dec 2016fiscal year | Dec 2017fiscal year | Dec 2018fiscal year | Dec 2019fiscal year | Dec 2020fiscal year | Dec 2021fiscal year | Dec 2022fiscal year | Dec 2023fiscal year | Dec 2024fiscal year | Dec 2025fiscal year | Last 12 monthsto Jun 2026 | Latest quarterJun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $16.19B | $16.80B | $15.83B | $12.59B | $14.40B | $32.58B | $29.27B | $8.70B | $12.74B | $11.70B | $13.40B | — |
| Capital spending | $1.82B | $1.96B | $1.98B | $2.05B | $2.23B | $2.71B | $3.24B | $3.91B | $2.91B | $2.63B | $2.42B | — |
| Free cash flow | $14.37B | $14.85B | $13.84B | $10.54B | $12.18B | $29.87B | $26.03B | $4.79B | $9.84B | $9.07B | $10.98B | — |
| Buybacks | $5.00B | $5.00B | $12.20B | $8.87B | $0 | $0 | $2.00B | $0 | $0 | $0 | — | — |
| Dividends | $7.32B | $7.66B | $7.98B | $8.04B | $8.44B | $8.73B | $8.98B | $9.25B | $9.51B | $9.77B | $9.79B | — |
| Returned to shareholders | $12.32B | $12.66B | $20.18B | $16.91B | $8.44B | $8.73B | $10.98B | $9.25B | $9.51B | $9.77B | $9.79B | — |
| Stock-based pay | $691.0M | $840.0M | $923.0M | $687.0M | $755.0M | $1.18B | $872.0M | $525.0M | $877.0M | $799.0M | $947.0M | — |
Where these numbers come from
Every column links to the filing it comes from on EDGAR. Last 12 months adds the latest year to date to the last 10-K and takes away the same months a year earlier. Debt is long-term debt including the part due within a year. A dash means the company did not report that line in a form we can read, never a zero. Market cap uses the latest closing price and the share count from the cover of the latest filing. How we count
Pfizer financials, answered
What is Pfizer's market cap?
$168.60B at $29.58 a share, with 5,699,673,589 shares outstanding as of Jul 29, 2026, from the cover of its latest SEC filing.
How much does Pfizer earn?
Revenue of $63.70B and net income of $4.33B in the last 12 months to Jun 2026.
How much debt does Pfizer have?
Pfizer reported $63.10B of debt and $976.0M of cash and equivalents on its balance sheet in Jun 2026.
Does Pfizer make free cash flow?
Yes. Operating cash flow minus capital spending was $10.98B in the last 12 months to Jun 2026.
How much cash does Pfizer return to shareholders?
$9.77B in buybacks and dividends in fiscal 2025, from the cash flow statement.